Browse Tag


WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19

4 mins read

The FINANCIAL -- The World Health Organization (WHO) listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for emergency use in all countries and for COVAX roll-out. The decision comes on the back of the European Medicines Agency (EMA) authorization, which was announced two days ago according to WHO.…

Johnson & Johnson Initiates second global Phase 3 clinical trial of its Janssen COVID-19 vaccine candidate

3 mins read

The FINANCIAL — The Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enroll and vaccinate study participants. ENSEMBLE is proceeding to enroll up to 60,000 participants worldwide. In addition to the…

Janssen’s coronavirus vaccine trials begin across the UK involving 6,000 volunteers

7 mins read

The FINANCIAL — Global pharmaceutical company Janssen will begin clinical trials of its potential vaccine in the UK from today (Monday 16 November), involving 6,000 volunteers across the country. The Janssen Pharmaceutical Companies, part of Johnson & Johnson, is the latest study in the UK, jointly funded by the UK government’s Vaccine Taskforce, to test…

EU gives green light to Johnson & Johnson to supply 200M doses of COVID-19 vaccine candidate

3 mins read

The FINANCIAL — Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of its COVID-19 vaccine candidate to EU Member States following approval or…